Exarafenib is under clinical development by Kinnate Biopharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Exarafenib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Exarafenib overview

Exarafenib is under development for the treatment of solid tumors, non-small cell lung cancer (NSCLC) and melanoma. It acts by targeting proto oncogene B Raf (BRAF). It is administered through oral route.

Kinnate Biopharma overview

Kinnate Biopharma is a biotechnology company that focuses on the discovery and development of small molecule kinase inhibitor candidates for difficult-to-treat, cancers associated with genetic alterations. It is advancing the development of its lead-targeted therapy FGFR and RAF candidates. The company harnesses the proprietary, unique co-crystal structure of KIN002787 in the BRAF protein and biomarker-driven approach to drive the preclinical and clinical development of its translational research programs. Kinnate Biopharma also carries out small molecule development programs, such as Cyclin-Dependent Kinase 12 (CDK12) inhibitor. It has operations in San Francisco, the US. Kinnate Biopharma is headquartered in San Diego, California, the US.

For a complete picture of Exarafenib’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.